Skip to main content
European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-30

Crosstalk Between Nitric and Carbon Monoxide in Suppressing the Pathogenesis of Cerebral Malaria

Objetivo

Malaria, can lead to the development of cerebral malaria (CM), a lethal syndrome that claims more then one million deaths per year. There is currently no effective treatment against CM. We have shown that the gas carbon monoxide (CO), generated via heme catabolism by heme oxygenase-1, inhibits the onset of CM in mice (1). While not affecting parasitemia per se, CO inhibits all the major pathologic hallmarks of CM, including blood brain barrier disruption, brain micro-vascular congestion and neuroinflammation. The mechanism underlying this protective effect relies on the ability of CO to bind the heme groups of cell free hemoglobin, released from infected red blood cells. Once bound to these heme groups CO suppresses their release, thus devoiding them from triggering CM (1). The same heme groups contained within cell free hemoglobin have been shown to scavenge endogenous nitric oxide (NO) and decrease its bioavailability, an effect shown to precipitate the onset of CM in mice (2). This suggests that as for CO, NO can also contribute to suppresses the development of CM. The central hypothesis to be tested under this proposal is that the protective effect of NO might rely on its well-established ability to induce the expression of heme oxygenase-1 and in this manner sustain the generation of CO. Once bound to the heme groups of cell-free hemoglobin, CO would inhibit heme release and in addition would increase NO bioavailability, thus generating a protective positive feed back loop in which NO would sustain the expression of heme oxygenase-1 and the generation of CO. Unveiling this functional interaction between NO and CO during Malaria infection might be useful not only to our understanding of the basic mechanisms underlying the pathogenesis of CM but also in developing new therapeutic strategies aimed at overcoming the devastating effects of this disease. 1. A. Pamplona et al., Nat Med 13, 703 (Jun, 2007). 2. I. Gramaglia et al., Nat Med 12, 1417 (Dec, 2006)

Convocatoria de propuestas

FP7-PEOPLE-2007-2-1-IEF
Consulte otros proyectos de esta convocatoria

Coordinador

FUNDACAO CALOUSTE GULBENKIAN
Aportación de la UE
€ 128 190,60
Dirección
AVENIDA BERNA 45A
1067-001 LISBOA
Portugal

Ver en el mapa

Región
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Tipo de actividad
Research Organisations
Contacto administrativo
Miguel Soares (Dr.)
Enlaces
Coste total
Sin datos